Prevention of venous thromboembolism in Wales: results of a survey among general surgeons.
OBJECTIVE
To examine the current attitudes towards the prevention of venous thromboembolism among a cohort of surgeons.


METHODS
A postal survey, comprising a questionnaire covering various aspects of venous thromboembolism prophylaxis was sent to all (n=84) consultant general surgeons in Wales.


RESULTS
Replies were received from 57 surgeons (68%), all of whom routinely used prophylaxis, the most frequent modalities used being heparin (100%) and graded compression stockings (79%). A combination of physical and pharmacological methods was used by over 89% of surgeons, with 60% starting prophylaxis more than two hours before operation. All surgeons continued prophylaxis after surgery, 53% until patients were mobile, 45% until they were discharged, and one surgeon continued prophylaxis for seven days after discharge. The thrombosis risk factors considered most important by surgeons when deciding about prophylaxis were (i) a previous history of venous thromboembolism, (ii) hypercoagulability, and (iii) malignancy.


CONCLUSIONS
This study confirms that Welsh surgeons conform to standard methods, but also highlights some uncertainties that are present in current surgical practice. Those who responded all routinely used prophylaxis, the timing of which was variable. The main risk factors identified when considering prophylaxis were previous history of deep vein thrombosis/pulmonary embolism, hypercoagulability, and the presence of malignancy. Suggestions for future practice are made.
Williams
E V
EV
Department of Surgery, Royal Glamorgan Hospital, Ynysmaerdy, Llantrisant, UK. eifion@vwilliams.freeserve.co.uk
Williams
R S
RS
Hughes
J L
JL
Williams
K L
KL
Foster
M E
ME
Lewis
M H
MH
D000925:Anticoagulants / Q000627:therapeutic use*; D001458:Bandages; D001778:Blood Coagulation Disorders / Q000150:complications; D003131:Combined Modality Therapy; D006493:Heparin / Q000627:therapeutic use*; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use; D006801:Humans; D009369:Neoplasms / Q000150:complications; D011183:Postoperative Complications / Q000517:prevention & control*; D010818:Practice Patterns, Physicians'; D012008:Recurrence; D013923:Thromboembolism / Q000175:diagnosis / Q000209:etiology / Q000517:prevention & control*
D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight; D006493:Heparin